|
SLC41A2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.23519999953403E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.13749999997026E-06 |
| Normal-vs-Stage2 |
2.696300E-02 |
| Normal-vs-Stage3 |
1.64462999999726E-05 |
| Normal-vs-Stage4 |
5.39959965628611E-10 |
| Stage1-vs-Stage2 |
2.542800E-01 |
| Stage1-vs-Stage3 |
7.169800E-01 |
| Stage1-vs-Stage4 |
7.917400E-03 |
| Stage2-vs-Stage3 |
1.916630E-01 |
| Stage2-vs-Stage4 |
1.318380E-02 |
| Stage3-vs-Stage4 |
5.604400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.3727999999319E-07 |
| Normal-vs-AfricanAmerican |
1.378030E-03 |
| Normal-vs-Asian |
2.24099999999172E-05 |
| Caucasian-vs-AfricanAmerican |
8.613800E-01 |
| Caucasian-vs-Asian |
7.076000E-01 |
| AfricanAmerican-vs-Asian |
6.874400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.81619999994886E-06 |
| Normal-vs-Female |
7.73699999956357E-07 |
| Male-vs-Female |
3.913400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64229999999321E-06 |
| Normal-vs-Age(41-60Yrs) |
5.59150000000175E-05 |
| Normal-vs-Age(61-80Yrs) |
3.06120000459487E-08 |
| Normal-vs-Age(81-100Yrs) |
4.446100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.983000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.212800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.950400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.170400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.943200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.867400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.186010E-02 |
| Classical-VS-Follicular |
5.086000E-01 |
| Classical-VS-Other |
8.938000E-02 |
| Classical-VS-Normal |
5.66459999999935E-05 |
| Tall-VS-Follicular |
1.873030E-01 |
| Tall-VS-Other |
2.300800E-01 |
| Tall-VS-Normal |
6.77779999902484E-08 |
| Follicular-VS-Other |
2.379000E-01 |
| Follicular-VS-Normal |
1.152090E-04 |
| Other-VS-Normal |
3.571000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.01299999999416E-06 |
| Normal-vs-N1 |
8.99940000298471E-09 |
| N0-vs-N1 |
3.992100E-02 |
|
|
